30% Flip Ideas

[Pennybuster]

$RXII recent news/filings

## source: finance.yahoo.com

Thu, 04 Jun 2015 20:32:24 GMT ~ RXI PHARMACEUTICALS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150604/rxii8-k.html
*********************************************************

Thu, 04 Jun 2015 18:30:00 GMT ~ 3 Stocks Under $10 to Trade for Breakouts


read full: http://www.thestreet.com/story/13175940/1/3-stocks-under-10-to-trade-for-breakouts.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Wed, 03 Jun 2015 11:04:00 GMT ~ 7:04 am RXi Pharma granted notice of allowance for patent covering lead compound, RXI-109, for use in the eye; will be scheduled to expire in 2031


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#rxii
*********************************************************

Wed, 03 Jun 2015 11:02:00 GMT ~ RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye

[PR Newswire] - MARLBOROUGH, Mass., June 3, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on its novel, self-delivering RNAi platform (sd-rxRNA®). The patent, titled "RNA Interference in Ocular Indications," covers methods of use of RXi's VEGF-targeting and CTGF-targeting self-delivering rxRNAs®, including RXI-109, for use in the eye. The patent, once issued, will be scheduled to expire in 2031. This core patent, within RXi's intellectual property portfolio, broadens the coverage of RXi's self-delivering platform and provides coverage of RXI-109 for the treatment of ocular fibrosis.

read full: http://finance.yahoo.com/news/rxi-pharmaceuticals-granted-notice-allowance-110200502.html
*********************************************************

Tue, 02 Jun 2015 11:02:00 GMT ~ RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology

[PR Newswire] - MARLBOROUGH, Mass., June 2, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced that Dr. Pamela Pavco, RXi's Chief Development Officer, will present at the 23rd World Congress of Dermatology (WCD). This six-day world congress will include in-depth presentations by world-class clinicians and/or investigators, dermatology forums for health professionals, patient advocacy and support forums and other plenary sessions.

read full: http://finance.yahoo.com/news/rxi-pharmaceuticals-present-23rd-world-110200006.html
*********************************************************

$RXII charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$RXII company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RXII/company-info
Ticker: $RXII
OTC Market Place: Not Available
CIK code: 0001533040
Company name: RXI Pharmaceuticals Corporation
Company website: http://www.rxipharma.com
Incorporated In: DE, USA

Business Description: RXi Pharmaceuticals Corporation (OTCQX:RXII) is a biotechnology company focused on discovering, developing, and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or \"RNAi,\" have great promise because of their ability to \"silence\" or down-regulate, the expression of a specific gene that may be expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human trial in 2012. RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.Less >>

$RXII share structure

## source: otcmarkets.com

Market Value: $14,178,380 a/o Jun 03, 2015
Shares Outstanding: 36,160,113 a/o May 08, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$RXII extra dd links

Company name: RXI Pharmaceuticals Corporation
Company website: http://www.rxipharma.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RXII/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RXII/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RXII+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RXII+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RXII+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RXII/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RXII/news - http://finance.yahoo.com/q/h?s=RXII+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RXII/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RXII/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RXII/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RXII/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RXII/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RXII/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RXII/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RXII/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RXII+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RXII
DTCC (dtcc.com): http://search2.dtcc.com/?q=RXI+Pharmaceuticals+Corporation&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=RXI+Pharmaceuticals+Corporation
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=RXI+Pharmaceuticals+Corporation&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.rxipharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.rxipharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.rxipharma.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RXII/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RXII
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RXII/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RXII/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RXII/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001533040&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RXII/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RXII/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RXII/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RXII/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RXII&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RXII
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RXII/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RXII+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RXII+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RXII
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RXII
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RXII+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RXII/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RXII+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RXII.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RXII
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RXII/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RXII/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RXII/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RXII/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RXII
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RXII
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RXII:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RXII
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RXII



$RXII DD Notes ~ http://www.ddnotesmaker.com/RXII